These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 23213094)

  • 1. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
    Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
    J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
    Shah MA; Wainberg ZA; Catenacci DV; Hochster HS; Ford J; Kunz P; Lee FC; Kallender H; Cecchi F; Rabe DC; Keer H; Martin AM; Liu Y; Gagnon R; Bonate P; Liu L; Gilmer T; Bottaro DP
    PLoS One; 2013; 8(3):e54014. PubMed ID: 23516391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
    Chia SK; Ellard SL; Mates M; Welch S; Mihalcioiu C; Miller WH; Gelmon K; Lohrisch C; Kumar V; Taylor S; Hagerman L; Goodwin R; Wang T; Sakashita S; Tsao MS; Eisenhauer E; Bradbury P
    Breast Cancer Res; 2017 May; 19(1):54. PubMed ID: 28464908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
    Yau TCC; Lencioni R; Sukeepaisarnjaroen W; Chao Y; Yen CJ; Lausoontornsiri W; Chen PJ; Sanpajit T; Camp A; Cox DS; Gagnon RC; Liu Y; Raffensperger KE; Kulkarni DA; Kallender H; Ottesen LH; Poon RTP; Bottaro DP
    Clin Cancer Res; 2017 May; 23(10):2405-2413. PubMed ID: 27821605
    [No Abstract]   [Full Text] [Related]  

  • 5. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
    Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
    Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
    Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
    Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
    J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
    Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
    Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the role of MET kinase in cancer therapy.
    Posadas EM; Figlin RA
    J Clin Oncol; 2013 Jan; 31(2):169-70. PubMed ID: 23213104
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
    Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
    JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
    Naing A; Kurzrock R; Adams LM; Kleha JF; Laubscher KH; Bonate PL; Weller S; Fitzgerald C; Xu Y; LoRusso PM
    Invest New Drugs; 2012 Feb; 30(1):327-34. PubMed ID: 20842406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
    Rayson D; Lupichuk S; Potvin K; Dent S; Shenkier T; Dhesy-Thind S; Ellard SL; Prady C; Salim M; Farmer P; Allo G; Tsao MS; Allan A; Ludkovski O; Bonomi M; Tu D; Hagerman L; Goodwin R; Eisenhauer E; Bradbury P
    Breast Cancer Res Treat; 2016 May; 157(1):109-16. PubMed ID: 27116183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
    Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
    Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
    Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
    Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
    Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
    Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
    Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Savolitinib for MET-driven papillary renal cell carcinoma.
    Gilbert JA
    Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
    [No Abstract]   [Full Text] [Related]  

  • 20. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
    Zillhardt M; Park SM; Romero IL; Sawada K; Montag A; Krausz T; Yamada SD; Peter ME; Lengyel E
    Clin Cancer Res; 2011 Jun; 17(12):4042-51. PubMed ID: 21551255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.